This week, Alnylam Pharmaceuticals launched its latest attack in an intellectual property lawsuit filed against the Whitehead Institute for Biomedical Research, the University of Massachusetts, and the Massachusetts Institute of Technology, questioning UMass' claim to ownership of certain IP at the heart of the dispute (see related story, this issue).
Although the suit was first filed last summer, the courtroom showdown had been brewing for years. Below is a snapshot of key events that led to the litigation.
